Chronic Fatigue Syndrome Advisory Committee

Last updated
Chronic Fatigue Syndrome Advisory Committee
AbbreviationCFSAC
Purposestudy of chronic fatigue syndrome
Location

The Chronic Fatigue Syndrome Advisory Committee (CFSAC) was formed in response to the use of funds by the United States Centers for Disease Control and Prevention in the study of chronic fatigue syndrome (CFS). The CFSAC was charted under the Public Health Service Act of the US and funded by the United States Department of Health and Human Services (HHS). The CFSAC advises the Secretary of Health and Human Services on issues related to its mandate, including issues related to access and care for individuals with CFS, research, public health, clinical care and education regarding CFS. In November, 2008, support for CFSAC activities was changed to the Office on Women's Health, a division of the Office of Public Health and Science. [1] It held it first meeting in 2003.

Contents

Recommendations

In 2010 the committee advised HHS that the name chronic fatigue syndrome (CFS) should be changed to CFS-ME because the name wasn't being taken seriously. ME stands for myalgic encephalomyelitis or myalgic encephalopathy, according to the panel. One member stated that a more serious-sounding name might encourage more research into the illness. The CFSAC panel also recommended that national CFS-ME network of treatment centers be created by HHS, "in order to expand access to care, to develop educational initiatives, and to allow researchers to share data." [2]

See also

Footnotes

  1. "Chronic Fatigue Syndrome Advisory Committee (CFSAC)". United States Department of Health and Human Services . Retrieved 2009-05-26.
  2. Walker, Emily P. (2010-10-15). "Panel Pushes for Chronic Fatigue Syndrome Name Change". MedPage Today . Retrieved 2011-08-08.

Related Research Articles

<span class="mw-page-title-main">ME Association</span> UK charitable organization

The ME Association is a UK health charitable organization that provides information, advocacy, and services to persons and families affected by ME/CFS, and raises funds for research into ME/CFS. It has been reported to be one of the two largest UK charities for ME/CFS.

Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). There is some evidence it may improve some ME/CFS symptoms.

The Solve ME/CFS Initiative is an American nonprofit that does research and advocacy for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long COVID, and other post-infectious diseases. Their stated mission is to assist research into ways to diagnose, treat, or cure these conditions. They also advocate for increased awareness, public funding of research, and access to medical care for patients.

<span class="mw-page-title-main">History of ME/CFS</span> Review of the topic

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has a long history with an evolution in medical understanding, diagnoses and social perceptions.

Treatment of ME/CFS is variable and uncertain, and the condition is primarily managed rather than cured.

<span class="mw-page-title-main">Controversies related to ME/CFS</span>

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an illness with a long history of controversy. Some professionals within the medical community do not recognize ME/CFS as a genuine condition, nor is there agreement on its prevalence. There has been much disagreement over the pathophysiology of chronic fatigue syndrome, how it should be diagnosed, and how to treat it.

<span class="mw-page-title-main">Clinical descriptions of ME/CFS</span> Review of the topic

Clinical descriptions of ME/CFS vary. Different groups have produced sets of diagnostic criteria that share many similarities. The biggest differences between criteria are whether post-exertional malaise (PEM) is required, and the number of symptoms needed. The pathology of ME/CFS is unknown, and it can be a difficult condition to diagnose because there is no standard test, many symptoms are non-specific, and because doctors and patients may be unfamiliar with post-exertional malaise. Subgroup analysis suggests that, depending on the applied definition, CFS may represent a variety of conditions rather than a single disease entity.

The Lightning Process (LP) is a three-day personal training programme developed and trademarked by British osteopath Phil Parker. It makes unsubstantiated claims to be beneficial for various conditions, including chronic fatigue syndrome, depression and chronic pain.

Patricia A. Fennell is the chief executive officer of Albany Health Management Associates. She is a clinician, research scientist, educator, and author specializing in chronic illness, chronic and post-viral syndromes, trauma, forensics, hospice, global health care concerns, autoimmune and post-viral disease, clinical education, and training.

Graded exercise therapy (GET) is a programme of physical activity that starts very slowly and gradually increases over time, intended as a treatment for chronic fatigue syndrome. Most public health bodies, including the CDC and NICE, consider it ineffective, and its safety is disputed. However, GET still enjoys support among a minority of clinicians and organizations.

David Sheffield Bell is an American physician who has done extensive research on the clinical aspects of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). He has also conducted evaluations and research in pediatric ME/CFS and written numerous articles about the condition.

Daniel Peterson is an American physician in private practice in the state of Nevada, and has been described as a "pioneer" in the treatment of chronic fatigue syndrome (CFS). He graduated from the University of Rochester School of Medicine, Rochester, New York, in 1976 and was an intern and resident at the University of Utah Medical Center from 1976 to 1979. In 1979, he became a diplomate of the American Board of Internal Medicine. He is president of Sierra Internal Medicine of Incline Village, established in 1981.

Leonard A. Jason is a professor of psychology at DePaul University in Chicago, Illinois, where he also directs the Center for Community Research. His chief professional interests include the study of chronic fatigue syndrome (CFS), violence prevention, smoking cessation, and Oxford House recovery homes for substance abuse. Jason's interest in chronic fatigue syndrome began when he was diagnosed with the condition in 1990 after having mononucleosis.

<span class="mw-page-title-main">Myalgic encephalomyelitis/chronic fatigue syndrome</span> Medical condition

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating long-term medical condition. People with ME/CFS experience lengthy flare-ups of the illness following relatively minor physical or mental activity. This is known as post-exertional malaise (PEM) and is the hallmark symptom of the illness. Other core symptoms are a greatly reduced ability to do tasks that were previously routine, severe fatigue, and sleep disturbances. The baseline fatigue in ME/CFS does not improve much with rest. Orthostatic intolerance, memory and concentration problems, and chronic pain are common. About a quarter of people with ME/CFS are severely affected and unable to leave their bed or home.

<span class="mw-page-title-main">Anthony L. Komaroff</span> American physician

Anthony L. Komaroff is an American physician, clinical investigator, editor, and publisher. He serves as the Distinguished Simcox-Clifford-Higby Professor of Medicine at Harvard Medical School and Senior Physician at Brigham and Women's Hospital in Boston.

Jennifer Brea is an American documentary filmmaker and activist. Her debut feature, Unrest, premiered at the 2017 Sundance Film Festival and received the US Documentary Special Jury Award For Editing. Brea also co-created a virtual reality film which premiered at Tribeca Film Festival.

Rosamund Vallings is a medical doctor, known as one of the leading authorities on Chronic Fatigue Syndrome (ME/CFS) in New Zealand.

<span class="mw-page-title-main">Post-exertional malaise</span> Worsening of symptoms with activity

Post-exertional malaise (PEM), sometimes referred to as post-exertional symptom exacerbation (PESE), is a worsening of symptoms that occurs after minimal exertion. It is the hallmark symptom of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and common in long COVID. PEM is often severe enough to be disabling, and is triggered by ordinary activities that healthy people tolerate. Typically, it begins 12–48 hours after the activity that triggers it, and lasts for days, but this is highly variable and may persist much longer. Management of PEM is symptom-based, and patients are recommended to pace their activities to avoid triggering PEM.

The Open Medicine Foundation (OMF) is a US-based charity that funds research into the illnesses myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia, post-treatment Lyme disease syndrome, and long COVID.

Andrew Melvin Ramsay (1901–1990) was a British physician, who is known for his research and advocacy on myalgic encephalomyelitis (ME), a chronic disease causing muscle weakness and cognitive dysfunction. Ramsay worked as a consultant at the Royal Free Hospital in London during a mysterious 1955 disease outbreak of what later became known as ME. He studied the disease and similar outbreaks elsewhere. Work by Ramsay showed that although ME seldom caused death, the disease could be highly disabling.